Next event
Stocks in the Vines - Investor Access Day 2026
BlinkLab (ASX:BB1) | Myopharm (Pre‑IPO) | Amplia Therapeutics (ASX:ATX) | Medigrowth Australia | Imunexus (Pre‑IPO)
10:00 am - 10:30 am: Registration and Networking
Begin your day by signing in and connecting with other attendees, presenters, and sector professionals. Enjoy morning tea and fresh barista coffee as you settle in.
10:00 am - 10:30 am: Registration and Networking
Begin your day by signing in and connecting with other attendees, presenters, and sector professionals. Enjoy morning tea and fresh barista coffee as you settle in.
10:35 AM - 10:45 AM: Opening Remarks
Our host opens the day with a warm welcome to Stocks in the Vines, setting the stage for a program built around discovery, innovation, and high‑value networking. Nathan Lodge, founder of Mines in the Vines Events, will guide you through the presenting companies.
10:35 AM - 10:45 AM: Opening Remarks
Our host opens the day with a warm welcome to Stocks in the Vines, setting the stage for a program built around discovery, innovation, and high‑value networking. Nathan Lodge, founder of Mines in the Vines Events, will guide you through the presenting companies.
10:55 AM – 11:10 AM: Medigrowth Australia
Co-Founder & Director, Todd McLellan, presents Medigrowth’s vision, clinical and commercial momentum, and its positioning within the fast‑growing medical‑therapeutics sector.
10:55 AM – 11:10 AM: Medigrowth Australia
Co-Founder & Director, Todd McLellan, presents Medigrowth’s vision, clinical and commercial momentum, and its positioning within the fast‑growing medical‑therapeutics sector.
11:10 AM – 11:25 AM: Amplia Therapeutics (ASX:ATX)
CEO and Managing Director Dr Burns provides insight into Amplia’s differentiated FAK‑inhibitor strategy, the progress of AMP945, and the company’s emerging clinical and commercial upside.
11:10 AM – 11:25 AM: Amplia Therapeutics (ASX:ATX)
CEO and Managing Director Dr Burns provides insight into Amplia’s differentiated FAK‑inhibitor strategy, the progress of AMP945, and the company’s emerging clinical and commercial upside.
11:25 AM - 11:45 AM: Networking Break
Refresh, recharge, and engage with peers during an open networking session.
11:25 AM - 11:45 AM: Networking Break
Refresh, recharge, and engage with peers during an open networking session.
11:45 AM - 12:00 PM: BlinkLab (ASX:BB1)
Non-Executive Chairman, Brian Leedman, returns to Stocks in the Vines with a high‑impact update onBlinkLab's latest milestones, including the advancement of its AI‑powered smartphone technology aimed at transforming early detection pathways for autism and ADHD — a rapidly emerging market with significant global demand.
11:45 AM - 12:00 PM: BlinkLab (ASX:BB1)
Non-Executive Chairman, Brian Leedman, returns to Stocks in the Vines with a high‑impact update onBlinkLab's latest milestones, including the advancement of its AI‑powered smartphone technology aimed at transforming early detection pathways for autism and ADHD — a rapidly emerging market with significant global demand.
12:00 PM - 12:15 PM: Imunexus (Pre:IPO)
A high‑value session where Philippa Lewis and Dr George Kopsidas reveal how Imunexus’ platform is unlocking a new generation of bispecific biologics by enhancing proven drugs, accelerating development, and reducing technical risk — a compelling proposition for investors seeking scalable biotech innovation.
12:00 PM - 12:15 PM: Imunexus (Pre:IPO)
A high‑value session where Philippa Lewis and Dr George Kopsidas reveal how Imunexus’ platform is unlocking a new generation of bispecific biologics by enhancing proven drugs, accelerating development, and reducing technical risk — a compelling proposition for investors seeking scalable biotech innovation.
12:15 PM - 12:30 PM: Myopharm (Pre-IPO)
Executive Chair and Founding CEO Karinza Phoenix shares how Myopharm is accelerating both its clinical and commercial strategy, with multiple value‑shaping updates emerging across its pipeline. As investor interest in healthcare and biotech continues to surge, Myopharm is positioning itself at the intersection of scientific innovation and real‑world patient impact.
12:15 PM - 12:30 PM: Myopharm (Pre-IPO)
Executive Chair and Founding CEO Karinza Phoenix shares how Myopharm is accelerating both its clinical and commercial strategy, with multiple value‑shaping updates emerging across its pipeline. As investor interest in healthcare and biotech continues to surge, Myopharm is positioning itself at the intersection of scientific innovation and real‑world patient impact.
12:30 PM - 2:00 PM: Lunch and Networking
Enjoy a relaxed lunch at the Meletos Estate and continue building connections with fellow delegates.
12:30 PM - 2:00 PM: Lunch and Networking
Enjoy a relaxed lunch at the Meletos Estate and continue building connections with fellow delegates.
2:15 PM - 3:30 PM: Optional Wine Blending Competition
Work in groups with fellow delegates as the Barrel Steward leads you through the craft of wine blending. Explore balance, structure, and flavour through guided tasting and hands‑on experimentation before teaming up to create your own signature blend. A spirited, collaborative competition that brings out your inner winemaker.
2:15 PM - 3:30 PM: Optional Wine Blending Competition
Work in groups with fellow delegates as the Barrel Steward leads you through the craft of wine blending. Explore balance, structure, and flavour through guided tasting and hands‑on experimentation before teaming up to create your own signature blend. A spirited, collaborative competition that brings out your inner winemaker.
4 PM: Closing remarks / event concludes
Nathan Lodge offers final reflections and thanks delegates as the day’s program comes to a close.
Buses and delegates depart.
4 PM: Closing remarks / event concludes
Nathan Lodge offers final reflections and thanks delegates as the day’s program comes to a close.
Buses and delegates depart.
Please note that the agenda is subject to change. Detailed session descriptions and speaker information will be confirmed 10 May 2026
Please note that the agenda is subject to change. Detailed session descriptions and speaker information will be confirmed by 10 May 2026.
